Genedata Announces Licensing Agreement with Gilead Sciences to Enhance Data Science Innovation in Discovery Research
Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced a licensing agreement with Gilead Sciences, Inc. to help the company leverage the power of multi-omics data in the discovery of life-changing therapeutics across multiple indications. The agreement includes a software license to Genedata Profiler®, a domain-specific, state-of-art data integration and analytics platform, and access to consulting resources to support the adoption and integration of the solution within the company’s infrastructure.
“At Gilead, we work every day to discover innovative therapeutics for people with life-threatening diseases,” said Li Li, Executive Director, Research Data Sciences at Gilead. “Utilizing Genedata Profiler will enhance our capabilities for integration and analysis of large-scale multi-modal datasets as we continue to accelerate research for the discovery of transformative medicines.”
As a comprehensive, end-to-end computational solution, Genedata Profiler enables biopharmaceutical organizations to conduct data-rich discovery and translational research and make more informed decisions, ultimately supporting the development of more effective, targeted treatments. It empowers data scientists to decipher complex patterns associated with a specific disease from Next Generation Sequencing (NGS) and other high-dimensional data, facilitating target identification and evaluation and biomarker research for a range of therapeutic indications.
The main benefits of Genedata Profiler include:
- A centralized data storage place to enable self-service access to a large variety of multi-omics data from past and ongoing experiments,
- Configurable automated workflows to streamline processing, integration, publishing, and analysis of a large amount of high-dimensional data,
- Advanced, yet intuitive analytical and visualization methods to help derive novel scientific insights,
- Efficient data-sharing tools with fine-grained access control to data to ensure seamless, yet secure collaboration across and beyond organizational units.
Beyond software, Genedata provides scientific domain expertise and 26 years of experience in supporting the biopharma industry in increasing the productivity and quality of their research output through digital transformation.
“We are excited to have signed Gilead Sciences to our rapidly growing customer list for our Genedata Profiler platform,” said Othmar Pfannes, Ph.D., CEO of Genedata. “Genedata Profiler democratizes access to R&D data and includes fit-for-purpose analytics, while automating highly complex data operations, all key requirements for enabling biopharmaceutical organizations to generate precision medicines as efficiently as possible.”
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.